-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

Benzinga·09/01/2026 16:46:08
Listen to the news
Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.